Curcumin Conjugates For Treating And Preventing Cancers

Abstract

Conjugating LHRH to curcumin (LHRH-Curcumin) substantially enhances the bioavailability of curcumin, targets it to cells expressing LHRH receptors, facilitates intravenous administration, and increases the anti-cancer efficacy of curcumin. The conjugate may be used against cancer cells that express the LHRH receptor: pancreas, prostate, breast, testicular, uterine, ovarian, melanoma. LH-Curcumin conjugates may be used against cancer cells that express the LH receptor: prostate, breast, ovary, testis, uterus, pancreas, and melanoma.


Claims
Download PDF
Document Preview
Document History
  • Publication: Apr 21, 2016
  • Application: Dec 21, 2015
    US US 201514977426 A
  • Priority: Dec 21, 2015
    US US 201514977426 A
  • Priority: May 31, 2011
    US US 201113119549 A
  • Priority: Sep 16, 2009
    US US 2009/0057141 W
  • Priority: Dec 9, 2008
    US US 12101908 P
  • Priority: Sep 19, 2008
    US US 9841408 P

Sign in to the Lens

Feedback